NASDAQ:FBLG
FibroBiologics, Inc.
FibroBiologics, Inc. reported net income of −$18.6M in fiscal 2025. Free cash flow was −$16.7M, and the diluted share count rose 35.8%.Summary generated from FibroBiologics, Inc.'s SEC filings. Latest annual report filed Feb 24, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−419.4%
Debt / equityn/a
Free cash flow−$16.7M
FCF marginn/a
Share count change+35.8%
Financials
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a |
| Operating income | −4 | −9 | −14 | −17 |
| Net income | −5 | −16 | −11 | −19 |
| Free cash flow | n/a | −7 | −12 | −17 |
Recent filings
- 8-KEntry into a material agreement
Oct 8, 2026 - 8-KResults of a shareholder vote
Sep 18, 2026 - 4Insider transaction report
Sep 15, 2026 - 8-KEntry into a material agreement
Sep 15, 2026 - 8-KDirector or officer change
Aug 24, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Jul 31, 2026 - DEF 14AProxy statement
Jul 31, 2026 - 8-KNotice of delisting or listing-rule failure
Jul 24, 2026